Clinical Trials Browser

Phase 2/3 × Active not recruiting × Carcinoma, Hepatocellular × Clear all

NCT04521153 2025-05-11

Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Phase 2/3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular